Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer

Oncology

Volumn 68, Issue 4-6, 2005, Pages 485-492

  Mok, Tony S K ^a,c   Kwok, Chi Lam ^a   Lee, Conrad ^a   Zhang, Li ^b   Wong, Herman ^a   Chan, Anthony T C ^a   Yeo, Winnie ^a   Yim, Anthony P C ^a   Chak, Karen ^a   Zee, Benny ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Etoposide, oral; Gemcitabine; Non platinum based chemotherapy; Non small cell lung cancer; Platinum based chemotherapy

Indexed keywords

CISPLATIN; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; LAMIVUDINE; METOCLOPRAMIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; APPETITE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; EMOTION; FEMALE; HAIR LOSS; HEPATITIS B; HUMAN; IMMUNE COMPLEX NEPHRITIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; SOCIAL STATUS; STATISTICAL SIGNIFICANCE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 23844548571     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086992     Document Type: Article

References (29)

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
2. Bunn PA, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998;4:1087-1100.
3. Le Chevalier T, Brisgand D, Douillard JY: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer. Results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-367.
4. Bonomi P, Kim K, Faircloough D: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 2000;18:623-631.
5. Sandler A, Nemunaitis J, Dehnam C: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000;18:122-130.
6. Schiller JH, Harrington D, Belani CP: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
7. Scagloiotti GV, De Marinis F, Rinaldi M: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
8. Douillard JY, Lerouge D, Monnier A: Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: A multicentre phase II study. Br J Cancer 2001;84:1179-1184.
9. Giaccone G, Smit EF, van Meerbeeck JP: A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. Ann Oncol 2000;11:109-112.
10. Laack E, Mende T, Benk J: Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: A phase II trial. Eur J Cancer 2001;37:583-590.
11. Gridelli C, Frontini L, Perrone F: Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: A phase II study of three different doses. Gem Vin Investigators. B J Cancer 2000;83:707-714.
12. Chen YM, Perng RP, Yang KY: A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IUB/ IV) non-small cell lung cancer. Chest 2000; 117:1583-1589.
13. Pectasides D, Kalofonos HP, Samantas E: An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic Co-Operative Oncology Group. Anticancer Res 2001;21:3005-3010.
14. Spiridonidis CH, Laufman LR, Carman L: Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial. Ann Oncol 2001;12:89-94.
15. Mok TS, Zee B, Chan ATC: A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer 2000;89:543-550.
16. Cardenal F, Lopez-Cabrerizo MP, Anton A: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:12-18.
17. Crino L, Scagliotti AV, De Marinis F: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999;17:3522-3530.
18. Aaronson NK, Ahmedzai S, Bergman B: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
19. Bergman B, Aaronson NK, Ahmedzai S: The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality Of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994;30:635-642.
20. Zhao H, Kanda K: Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res 2000;9:129-137.
21. Simon R, Wittes R, Ellenberg S: Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-1381.
22. Gridelli C, Perrone F, Palmeri S, D'Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR: Mitomycin plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The 'Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.). Ann Oncol 1996;7:821-826.
23. Gatzemeier U, Heckmayr M, Hossfeld DK: A randomized trial with mitomycin-C/ifos-famide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small-cell lung cancer. Am J Clin Oncol 1991;14:405-411.
24. Kosmidis P, Mylonakis N, Nicolaides C: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 2002;20:3578-3585.
25. Chen YM, Perng RP, Lee YC: Pachtaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: A randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol 2002;13:108-115.
26. van Meerbeeck JP, Smit EF, Lianes P: A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (abstract 1228). Proc Am Soc Clin Oncol 2001;20:308a.
27. Georgoulias V, Papadakis E, Alexopoulos A: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomized multicentre trial. Lancet 2001;357:1478-1484.
28. Sandler AB, Nemunaitis J, Denham C: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122-130.
29. Slevin ML: The clinical pharmacology of etoposide. Cancer 1991;67(suppl 1):319-329.